We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Genetic Mutation Discovered in Familial Chronic Diarrhea Syndrome

By LabMedica International staff writers
Posted on 01 Apr 2012
One heritable DNA mutation has been discovered that leads to chronic diarrhea and bowel inflammation, which contributes the pathology of the diseases. More...


A protein made from a specific gene is involved in transmitting specific chemical signals from food consumed to the cells inside the bowels, but family members with chronic diarrhea have a mutation that makes the protein transmit more signal than it should.

Investigators at HudsonAlpha Institute for Biotechnology (Huntsville, AL, USA) working with scientists from Norway and India, studied a Norwegian family with a number of related inflammatory bowel conditions. There were 32 affected persons from three branches of the same family as well as 14 unaffected family members. Such a large family allowed scientists in Norway to use traditional methods to narrow down the potential DNA mutation to one portion of chromosome 12, and then to a specific gene called guanylate cyclase 2C (GUCY2C). They used linkage analysis, based on arrays with single-nucleotide polymorphisms (SNPs), to identify a candidate region.

Genomic DNA was purified from blood with the use of the QIAsymphony system (Qiagen, Germantown, MD, USA). Whole-genome genotyping of SNPs was performed with the use of GeneChip Human Mapping Array (Affymetrix, Santa Clara, CA, USA). Linkage analysis of samples from 11 affected members and 14 healthy members of one family branch revealed only one significant shared region in the affected members, on the short arm of chromosome 12. The scientists are now evaluating possible drug treatments based on the function of the affected protein. They can also recommend that GUCY2C be reexamined in more common bowel inflammation syndromes, as it may contribute to pathology for thousands of people worldwide.

Shawn E. Levy, PhD, a faculty investigator at HudsonAlpha said, "Based on the effects seen from this one mutation, we are hopeful that the work will aid in understanding of much more common diseases like Crohn's and irritable bowel syndrome, which also have inflammation and diarrhea as symptoms." The study was published on March 21, 2012, in the New England Journal of Medicine (NEJM).

Related Links:
HudsonAlpha Institute
Qiagen
Affymetrix



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.